Advertisement

Prospects for New Hypoxic Cell Radiosensitizers

  • J. G. Schwade
  • D. A. Pistenma
  • T. L. Phillips
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 43)

Abstract

The hypoxic cell radiosensitizers misonidazole and metronidazole are currently being evaluated in clinical trials in North America and Europe. The usefulness of both compounds is limited by toxicity and pharmacology. Alternative routes of administration, or pharmacokinetic modification may decrease these problems. However, it is likely that development of new compounds with desirable physical and biological properties may be necessary in order to effect clinically useful radiosensitization. The status of currently available drugs, the National Cancer Institute program for development of new radiosensitizers (1), and the prospects for some compounds resulting from that program will be reviewed.

Keywords

National Cancer Institute Hypoxic Cell Radiation Sensitizer Drug Development Program Pharmacokinetic Curve 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Report of NCI Radiosensitizer/Radioprotector Working Group. Available from Radiation Development Branch, DCT, NCI (1980).Google Scholar
  2. 2.
    T. H. Wasserman, J. Stetz and T. L. Phillips, Cancer trials of misonidazole in the United States, p.387 in; “Radiation Sensitizers: Their Use in the Clinical Management of Cancer”, Cancer Management, Vol.5, ed. L.W. Brady, Masson Publishing USA Inc., New York (1980).Google Scholar
  3. 3.
    S. Dische, M. I. Saunders, I. R. Flockhart, M. E. Lee and P. Anderson, Misonidazole: A drug for trial in radiotherapy and oncology, Int. J. Radiat. Oncol. Biol. Phys. 5:851 (1979).PubMedCrossRefGoogle Scholar
  4. 4.
    J. G. Schwade, J. M. Strong, D. Gangji and E. Glatstein, Phase I trial of intravenous misonidazole (NSC 261037), Proc. Am. Soc. Clin. Onc. 21:396 (1980).Google Scholar
  5. 5.
    J. G. Schwade, J. M. Strong and D. Gangji, I.V. misonidazole (NSC 261037): report of initial clinical experience, p.414 in: “Radiation Sensitizers: Their Use in the Clinical Management of Cancer”, Cancer Management, Vol.5, ed. L.W. Brady, Masson Publishing USA Inc., New York (1980).Google Scholar
  6. 6.
    P. Workman, N. M. Bleehen and C. Wiltshire, Phenytoin shortens the half-life of the hypoxic cell radiosensitizer misonidazole in man: implications for possible reduced toxicity, Br. J. Cancer 41:307 (1980).CrossRefGoogle Scholar
  7. 7.
    D. Gangji, D. G. Poplack, J. Schwade, J. H. Wood and J. M. Strong, Misonidazole blood and cerebrospinal fluid kinetics in monkeys following intravenous and intrathecal administration, Eur. J. Cancer 17:29 (1981).PubMedCrossRefGoogle Scholar
  8. 8.
    J. M. Strong, J. G. Schwade, D. Gangji, D. D. Shoemaker and D. K. Upton, p.73 in: “Radiation Sensitizers: Their Use in the Clinical Management of Cancer”, Cancer Management, Vol. 5, ed. L.W. Brady, Masson Publishing USA Inc., New York (1980).Google Scholar
  9. 9.
    T. A. Rich, S. Dische, M. I. Saunders, M. Stratford and A. Michinton, p.411 in: “Radiation Sensitizers: Their Use in the Clinical Management of Cancer”, Cancer Management, Vol. 5, ed. L.W. Brady, Masson Publishing USA Inc., New York (1980).Google Scholar
  10. 10.
    Committee for Radiation Oncology Studies Research Plan: Radiation Sensitizers, Cancer 37:2062 (1976).Google Scholar
  11. 11.
    De Vita et al., Cancer Clin. Trials 2:195 (1979).Google Scholar
  12. 12.
    T. L. Phillips, T. H. Wasserman, R. J. Johnson, The hypoxic cell sensitizer program in the US, Br. J. Cancer 37 (Suppl.III): 276 (1978).Google Scholar
  13. 13.
    J. M. Brown and P. Workman, Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole, Rad. Res. 82:171 (1980).CrossRefGoogle Scholar
  14. 14.
    D. R. Goffinet and J. M. Brown, Comparison of intravenous and intra-arterial pyrimidine infusion as a means of radio-sensitizing tumours in vivo, Radiology 124:819 (1977).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • J. G. Schwade
    • 1
  • D. A. Pistenma
    • 2
  • T. L. Phillips
    • 3
  1. 1.Radiation Oncology Branch, Clinical Oncology Program, Division of Cancer TreatmentNCIUSA
  2. 2.Radiation Development Branch, Cancer Therapy, Evaluation Program, Division of Cancer TreatmentNCIUSA
  3. 3.Department of Radiation TherapyUniversity of CaliforniaSan FranciscoUSA

Personalised recommendations